Trial Profile

Resminostat tolerability, pharmacokinetics and pharmacodynamics in cancer patients (phase I trial)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resminostat (Primary)
Indications Lymphoma; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

18 Sep 2009 Results will be presented at the ECCO - ESMO Cancer Conference on 21 September 2009, according to a 4SC media release.
02 Jun 2009 Results presented at ASCO 2009.
09 Dec 2008 Final evaluation of all data is planned for the first quarter of 2009.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com